Avidity Biosciences, Inc Total Liabilities
Avidity Biosciences, Inc total liabilities. Based on the latest financial reports, Avidity Biosciences, Inc (RNAM) has total liabilities worth $269.45 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Avidity Biosciences, Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Avidity Biosciences, Inc (2018–2025)
Total liabilities of Avidity Biosciences, Inc from 2018 to 2025. This chart illustrates how Avidity Biosciences, Inc's total liabilities have evolved over time, based on quarterly financial data.
Avidity Biosciences, Inc Competitors by Total Liabilities
The table below lists competitors of Avidity Biosciences, Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CSPC PHARMACEUT.GR. ADR4
F:CVGU
|
Germany | €16.59 Billion |
|
First Horizon Corporation
NYSE:FHN
|
USA | $74.97 Billion |
|
REXEL S.A. ADR EO 5
F:E7V0
|
Germany | €8.96 Billion |
|
Novatek Microelectronics Corp
TW:3034
|
Taiwan | NT$31.74 Billion |
|
Fuzhou Rockchip Electronics Co Ltd
SHG:603893
|
China | CN¥873.35 Million |
|
Bangkok Bank PCL
BK:BBL
|
Thailand | ฿4.03 Trillion |
|
Shanghai Electric Group Co Ltd
SHG:601727
|
China | CN¥239.40 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Avidity Biosciences, Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see RNAM asset base.
Liquidity & Leverage Metrics
Avidity Biosciences, Inc Total Liabilities Ratios Explained
Avidity Biosciences, Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Avidity Biosciences, Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Avidity Biosciences, Inc (2018–2025)
The table below shows the annual total liabilities of Avidity Biosciences, Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $269.45 Million | +93.94% |
| 2024-12-31 | $138.94 Million | +8.72% |
| 2023-12-31 | $127.79 Million | +110.44% |
| 2022-12-31 | $60.73 Million | +31.58% |
| 2021-12-31 | $46.15 Million | +66.76% |
| 2020-12-31 | $27.68 Million | -82.94% |
| 2019-12-31 | $162.26 Million | +259.70% |
| 2018-12-31 | $45.11 Million | -- |
About Avidity Biosciences, Inc
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in… Read more